Stationary biofilm growth normalizes mutation frequencies and mutant prevention concentrations in Pseudomonas aeruginosa from cystic fibrosis patients.

García-Castillo, M; del Campo, R; Baquero, F; Morosini, M-I; Turrientes, M-C; Zamora, J; Cantón, R

García-Castillo, M; del Campo, R; Baquero, F; Morosini, M-I; Turrientes, M-C; Zamora, J; Cantón, R.

Affiliation

García-Castillo M; Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Madrid, Spain.

Clin Microbiol Infect ; 17(5): 704-11, 2011 May.

Article in En | MEDLINE | ID: mdl-20673272

Subject(s)

Biofilms; Cystic Fibrosis/microbiology; Mutation; Pseudomonas Infections/microbiology; Pseudomonas aeruginosa/genetics; Anti-Bacterial Agents/therapeutic use; Biofilms/drug effects; Ceftazidime/pharmacology; Ciprofloxacin/pharmacology; Cystic Fibrosis/drug therapy; Drug Resistance, Bacterial; Genetic Variation; Humans; Imipenem/pharmacology; Microbial Sensitivity Tests; Pseudomonas Infections/drug therapy; Pseudomonas Infections/genetics; Pseudomonas aeruginosa/drug effects; Pseudomonas aeruginosa/physiology; Respiratory System/microbiology; Tobramycin/pharmacology

Fulltext

XML

PubMed Links

Search on Google

Full text: 1 Collection: 01-internacional Health context: 1_ASSA2030 Database: MEDLINE Main subject: Pseudomonas aeruginosa / Pseudomonas Infections / Biofilms / Cystic Fibrosis / Mutation Limits: Humans Language: En Journal: Clin Microbiol Infect Year: 2011 Document type: Article

Fulltext

XML

PubMed Links

Search on Google